Spine Conditions

Resource Center

News
Research Summaries
Resources
FDA Alerts Pearls of Wisdom From the Journal
Insights
Commentary Podcasts Q&As Videos
Interactive
Polls Quizzes Slideshows
Events & Education

FDA Alerts

FDA Approval
FDA phone screen
FDA Approval
FDA Approves Isembyld as First Spinal Muscular Atrophy Therapy Targeting Muscle Loss
09/15/2026
Anthony Calabro, MA
A 52-week trial evaluated apitegromab-mstn as an adjunct to SMN2-targeted treatment in patients with spinal muscular atrophy who could not move or walk independently, demonstrating improved motor function...
09/15/2026
Spinal Muscular Atrophy
Spinal Muscular Atrophy
FDA Approves Option for Spinal Muscular Atrophy
08/10/2020
The US Food and Drug Administration has approved an oral drug for the treatment of spinal muscular atrophy among patients aged 2 years or older.
08/10/2020